Literature DB >> 15894978

Why do patients fail to receive beta-blockers for chronic heart failure over time? A "real-world" single-center, 2-year follow-up experience of beta-blocker therapy in patients with chronic heart failure.

Anoop C Parameswaran1, W H Wilson Tang, Gary S Francis, Ritesh Gupta, James B Young.   

Abstract

BACKGROUND: The longitudinal pattern of beta-blocker use in a heart-failure practice setting has not been explored. Previous studies have not specifically addressed the use of beta-blockers over time to determine the rate of use and reasons for discontinuation. The long-term compliance rate for beta-blocker drugs outside the context of a clinical trial has not been established.
METHODS: We prospectively followed a cohort of 500 consecutive patients between March and May 2001, with a clinical diagnosis of chronic heart failure seen in a specialized heart failure clinic and determined the longitudinal pattern of beta-blocker use and clinical outcomes over a 2-year period.
RESULTS: The final cohort consists of 340 patients with a complete 2-year follow-up data (mean age 61 +/- 14 years, 69% men, 53% with ischemic etiology, mean ejection fraction 27.6 +/- 15%). At 6, 12, and 24 months, beta-blocker utilization rates were maintained in 69%, 70%, and 74% of patients, respectively. Of the 120 confirmed initial non-beta-blocker users, 28 (23%) were subsequently started on beta-blocker, despite suspected relative contraindications in 53% of patients. Over a period of 2 years, the discontinuation rate was 10%, with failure to restart a beta-blocker after hospitalization as the most common reason for beta-blocker discontinuation.
CONCLUSION: Utilization rates of beta-blockers in our heart failure clinic have remained constant at approximately 70% throughout a 2-year follow-up. Of those who discontinued beta-blockers (10%), the most common documented cause was failure to restart beta-blockers after hospitalization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15894978     DOI: 10.1016/j.ahj.2004.07.026

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

1.  Age and receipt of guideline-recommended medications for heart failure: a nationwide study of veterans.

Authors:  Michael A Steinman; John B Harlow; Barry M Massie; Peter J Kaboli; Kathy Z Fung; Paul A Heidenreich
Journal:  J Gen Intern Med       Date:  2011-05-21       Impact factor: 5.128

2.  Racial Differences in Trends and Prognosis of Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction: the Atherosclerosis Risk in Communities (ARIC) Surveillance Study.

Authors:  Lena Mathews; Ning Ding; Yingying Sang; Laura R Loehr; Jung-Im Shin; Naresh M Punjabi; Alain G Bertoni; Deidra C Crews; Wayne D Rosamond; Josef Coresh; Chiadi E Ndumele; Kunihiro Matsushita; Patricia P Chang
Journal:  J Racial Ethn Health Disparities       Date:  2022-01-10

3.  Trends and inequities in beta-blocker prescribing for heart failure.

Authors:  Sunil M Shah; Iain M Carey; Stephen DeWilde; Nicky Richards; Derek G Cook
Journal:  Br J Gen Pract       Date:  2008-12       Impact factor: 5.386

4.  Prevalence of Guideline-Directed Medical Therapy for Cardiovascular Disease Among Baltimore City Adults in the Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS) Study.

Authors:  Lena Mathews; Dingfen Han; Michele K Evans; Alan B Zonderman; Chiadi E Ndumele; Deidra C Crews
Journal:  J Racial Ethn Health Disparities       Date:  2021-02-16

5.  Patient Medication Adherence and Physician Prescribing among Congestive Heart Failure Patients of Yemen.

Authors:  K M Alakhali; P S Daniel; A M Noohu; S A Sirajudeen
Journal:  Indian J Pharm Sci       Date:  2013-09       Impact factor: 0.975

6.  Resting heart rate in ambulatory heart failure with reduced ejection fraction treated with beta-blockers.

Authors:  Kenneth D Varian; Xinge Ji; Justin L Grodin; Frederik H Verbrugge; Alex Milinovich; Michael W Kattan; W H Wilson Tang
Journal:  ESC Heart Fail       Date:  2020-08-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.